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Abstract
Background: Improved glycemic control reduces complications in patients with diabetes mellitus (DM). However, it is
discussed controversially whether patients with diabetes mellitus and end-stage renal disease benefit from strict glycemic
control.
Methods: We followed 78 patients with DM initiating dialysis treatment of the region of Vorarlberg in a prospective cohort
study applying a time-dependent Cox regression analysis using all measured laboratory values for up to more than seven
years. This resulted in 880 HbA1c measurements (with one measurement every 3.16 patient months on average) during the
entire observation period. Non-linear P-splines were used to allow flexible modeling of the association with mortality and
cardiovascular disease (CVD) events.
Results: We observed a decreased mortality risk with increasing HbA1c values (HR=0.72 per 1% increase, p=0.024).
Adjustment for age and sex and additional adjustment for other CVD risk factors only slightly attenuated the association
(HR=0.71, p=0.044). A non-linear P-spline showed that the association did not follow a fully linear pattern with a highly
significant non-linear component (p=0.001) with an increased risk of all-cause mortality for HbA1c values up to 6–7%.
Causes of death were associated with HbA1c values. The risk for CVD events, however, increased with increasing HbA1c
values (HR=1.24 per 1% increase, p=0.048) but vanished after extended adjustments.
Conclusions: This study considered the entire information collected on HbA1c over a period of more than seven years.
Besides the methodological advantages our data indicate a significant inverse association between HbA1c levels and all-
cause mortality. However, for CVD events no significant association could be found.
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Introduction
It is well documented that improved glycemic control reduces
complications in patients with diabetes mellitus (DM) [1], how-
ever, it is not clear whether patients with DM and end-stage renal
disease (ESRD) benefit from strict glycemic control [2]. NKF-K/
DOQI guidelines recommend a target HbA1c of ,7% for patients
with DM and chronic kidney disease [3].
A prospective interventional study in patients with DM but
without renal failure showed an increase in all-cause mortality
in patients with HbA1c ,6% attained by intensive therapy
compared to the standard therapy group [4]. Nonetheless some
small observational studies mostly performed in Asian popu-
lations indicate the importance of good glycemic control for
survival in dialysis patients with DM [5–9]. One observational
study from Germany found higher HbA1c values to be a risk
factor for all-cause mortality and cardiovascular disease [10].
However, in several studies no association between HbA1c and
neither patient survival [11–15] nor cardiovascular disease
[12] could be shown in dialysis patients with DM. Most of
these studies were based on a single measurement of HbA1c
values. Only two studies considered time-dependent analyses
using all available measurements of HbA1c during the whole
observation period instead of using only a baseline measure-
ment [13,16].
Our single-center study aimed to investigate the association
of HbA1c values with mortality in a prospective observational
inception cohort of 78 dialysis patients with DM initiating di-
alysis treatment and followed for a period of up to more than
seven years. To consider the broad spectrum of intraindividual
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well as all other covariates recorded during the entire observation
period were considered in the time-dependent Cox regression
modeling. This resulted in 880 HbA1c measurements during the
entire observation period which were used in the analysis.
Furthermore, non-linear P-splines were applied to allow flexible
modeling of the association with mortality, CVD events and the
combination of CVD and peripheral arterial disease (PAD) events.
Our study is up to now the only inception cohort study with time-
dependent measurements over a long observation period.
Methods
INVOR-Study
The INVOR-Study [17] (Study of Incident Dialysis Patients in
Vorarlberg) is a single-center, prospective, observational cohort
study of incident Caucasian hemodialysis and peritoneal dialysis
patients in Vorarlberg, the westernmost province of Austria
counting approximately 400,000 inhabitants.
Ethic statement: The study was approved by the ethics
committee of the Innsbruck Medical University and all patients
enrolled in the study provided written informed consent.
All dialysis patients from this province starting chronic dialysis
treatment between May 1st, 2000 and April 30th, 2006 were
consecutively enrolled with the advantage that all patients of this
region are treated by the same care provider. During this period of
6 years a total number of 235 incident dialysis patients were
included and followed until the study endpoint was reached or
follow-up was censored at December 31st, 2007. Ten patients
having a malignant tumor at initiation of dialysis were not
recruited defined by the exclusion criteria. 82 out of 235 patients
were diagnosed with DM at baseline, 4 of them died shortly after
initiation of dialysis without having a sufficient number of HbA1c
measurements. Therefore 78 patients were considered for anal-
yses, 73 of them diagnosed with DM type 2 and 5 of them with
DM type 1. All data and analyses described in this manuscript are
based on these 78 patients.
Patients were treated according to the European Best Practice
Guidelines in place at the time of treatment (http://www.
ndt-educational.org/guidelines.asp).
Data description
As described recently clinical, laboratory and medication data
were collected prospectively starting at the time of initiation of
dialysis [17,18]. Laboratory parameters were recorded continu-
ously during the study period and measured in a central labo-
ratory. They were measured at different time intervals, most of
them once to twice monthly (hemoglobin, erythrocytes, creati-
nine, calcium and phosphorus), or every 3 months (HbA1c,
albumin, C-reactive protein and ferritin). The patients had a
median number of 10 HbA1c measurements in the follow-up
period (with a minimum of 1 and a maximum of 43 mesure-
aments) resulting in 880 different HbA1c measurements during
the entire observation period and one measurement every 3.16
patient months on average. Quality control is conducted twice a
year where the laboratory takes part at the trial of the Austrian
Society for Quality assurance and standardization of diagnostic
medical tests (O ¨ QUASTA). The methodology was evaluated in
our center regarding CLSI (Clinical and Laboratory Standards
Institute) Evaluation Protocol 10. The intra-assay variability was
1.04% for HbA1c of 5.3, 0.79% for 8.3 and 1.46% for 12.5. All
available measurements of HbA1c and the other variables were
used in the time-dependent Cox regression modeling described
below.
Study Outcomes
The outcomes of interest were all-cause mortality as well as
CVD events and the combination of CVD and PAD events. CVD
events were defined as fatal and non-fatal myocardial infarction
(diagnosed by clinical appearance, electrocardiography, increase
in troponin T and CK-MB and in most cases followed by
angiograpgy or autopsy in fatal cases), percutaneous transluminal
coronary angioplasty, aortocoronary bypass, angiographically
proven coronary stenosis $50%, sudden cardiac death, ischemic
or hemorrhagic cerebral infarction (diagnosed by clinical appear-
ance, CT or MRI or autopsy), transient ischemic attack, carotid
stenosis and carotid endarterectomy). Death causes were autopsy-
proven in 27% of the present patient sample. For PAD at least one
of the following events was existent: significant ultrasound- or
angiographically-proven vascular stenosis, percutaneous translu-
minal angioplasty, peripheral bypass or amputation. An incident
PAD event was only considered as a first time manifestation or a
deterioration of PAD in terms of e.g. a change in PAD stage
according to Fontaine. One patient was lost to follow-up because
of regaining renal function.
Statistical Methods
At baseline, categorical data were compared using x
2-test,
continuous variables were analyzed using an unpaired T-test or
the nonparametric Mann-Whitney-U-test. Associations between
all measured HbA1c values ,7% and various parameters we
investigated using linear mixed effects models. To investigate the
influence of HbA1c levels on all-cause mortality, a time-dependent
Cox Proportional Hazards model was used allowing all variables
to vary over different measurements during the whole observation
time for each patient. That is, each time-span between two suc-
cessive measurements enters the model independently. Each
covariate that entered the model was updated at the time they
were measured and modeled in a time-dependent fashion. If not
all variables were measured at a particular date, the respective
missing values were replaced by the values measured at the last
observation of this variable (‘‘last observation carried forward’’).
To account for possible correlation of values within one patient
robust variances were estimated, which were grouped for each
patient. The Proportional Hazards assumption was tested for each
model by testing for zero slopes of scaled Schoenfeld residuals.
At first, HbA1c was included linearly in the model with hazard
ratios referring to 1% increase. In order to evaluate the functional
form of the HbA1c effects, non-linear P-splines of degree 3 were
estimated. A spline of degree 3 is a linear combination of cubic
functions, which can fit virtually any smooth curve to the data.
Therefore, the analysis was not restricted to a potential linear
relationship of HbA1c with risk of mortality. To keep the number
of parameters estimated at a minimum, the minimum number of
knots for a non-linear P-spline was chosen (df=2). The spline term
can be split into its linear and non-linear components, which can
each be tested separately. For the linear term, a Hazard Ratio
(HR) can be estimated, whereas the non-linear component can be
depicted in a plot of the log(HR).
Cox models were calculated univariately including the time-
dependent HbA1c measurements and additionally adjusted for age
and sex. An extended model was also conducted, additionally
adjusting for CVD events before start of renal replacement
therapy and the time-dependent variables systolic and diastolic
blood pressure, hemoglobin, C-reactive protein, albumin. Due to
the high correlation of these factors with inflammation and
malnutrition, adding them as proxies in the model can adjust the
presence of inflammation and malnutrition partly. We also
performed a sensitivity analysis with censoring at the time of
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package ‘‘survival’’.
Results
Table 1 presents the baseline demographic and laboratory
characteristics as well as comorbidities before the start of dialysis
treatment of 78 patients with DM (46 men and 32 women). The
median follow-up time was 31.9 months. During this period, 33
patients died (42.3%). 17 patients died of cardiovascular disease
(51.0% of the death causes), 8 died of a fatal sepsis (25.5%) and 8
patients had other causes of mortality (23.5%).
Baseline laboratory parameters did not differ significantly
between survivors and non-survivors. The median duration of
diabetes mellitus was 15 years. HbA1c values were slightly lower in
survivors than in non-survivors, if only the measurements at start
of dialysis were considered, however, this difference was not
significant. If measurements 3 months after start of dialysis were
considered, HbA1c values were very similar in survivors and non-
survivors. Taking all measurements during the whole observation
period into account, HbA1c values were also lower in survivors
compared to non-survivors (mean [95% CI]: 7.01 [6.98; 7.05] vs.
7.36 [7.30; 7.42]. Figure 1 shows the distribution of all measured
HbA1c values in the two groups.
Table 1. Clinical characteristics of patients at baseline and during follow-up stratified by survival and by CVD events.
All patients Survivors Non-Survivors No CVD events CVD events**
(n=78) (n=45) (n=33) (n=40) (n=38)
Sex (male/female), n (%) 46/32 (59/41%) 28/17 (62/38%) 18/15 (55/45%) 23/17 (58/43%) 23/15 (61/39%)
Age (years) 65.569.2 65.369.2 65.869.3 68.869.3 62.167.8
c
Body Mass Index (kg/m
2) 27.864.5 28.264.0 27.265.1 27.464.8 28.264.2
Start of dialysis with
Hemodialysis, n (%) 73 (94%) 45 (100%) 28 (85%)
a 38 (95%) 35 (92%)
Central venous catheter, n (%) 12 (16%) 6 (13%) 6 (21%) 9 (24%) 3 (9%)
Native fistula, n (%) 49 (67%) 29 (64%) 20 (71%) 23 (61%) 26 (74%)
Graft, n (%) 12 (16%) 10 (22%) 2 (7%) 6 (16%) 6 (17%)
Peritoneal dialysis, n (%) 5 (6%) 0 (0%) 5 (15%)
a 2 (5%) 3 (8%)
Systolic blood pressure (mmHg) 159624 160623 158626 158622 160627
Diastolic blood pressure (mmHg) 82613 84613 79613 80612 84614
Duration of diabetes mellitus (years) 16.0610.7 15.069.7 17.5611.9 14.569.2 17.7612.0
Laboratory parameters
HbA1c (% Hb) at initiation of dialysis 7.1161.55 6.9461.42 7.3261.70 6.7361.10 7.5461.86
a
3 months after initiation of dialysis 7.3261.42 7.3161.36 7.3361.52 6.8060.98 7.7961.59
c
Albumin (g/dL) 3.660.6 3.760.5 3.560.5 3.460.6 3.760.4
a
C-reactive protein (mg/dL) 3.064.5
[ 0 . 4 ;1 . 1 ;3 . 1 ]
3.364.6
[0.4; 1.2; 4.7]
2.664.4
[0.3; 0.9; 2.2]
3.665.1
[ 0 . 6 ;1 . 6 ;4 . 4 ]
2.463.9
[0.3; 0.8; 2.2]
Phosphorus (mmol/L) 2.0160.63 1.9760.66 2.0760.60 2.0160.73 2.0160.52
Hemoglobin (g/dL) 11.261.6 11.461.6 11.061.6 11.161.5 11.361.6
Creatinine (mg/dL) 6.462.4 6.261.9 6.662.9 6.061.8 6.762.8
Ferritin (ng/mL) 1576165
[51; 116; 196]
1546159
[53; 112; 194]
1616175
[44; 137; 200]
1786189
[40; 149; 207]
1346132
[61; 111; 171]
Comorbidities before dialysis
CAD events*, n (%) 17 (22%) 9 (20%) 8 (24%) 9 (23%) 8 (21%)
CVD events**, n (%) 33 (42%) 17 (38%) 16 (49%) 14 (35%) 19 (50%)
PAD events***, n (%) 22 (28%) 13 (29%) 9 (27%) 13 (33%) 9 (24%)
Follow-up
Follow-up time (months){ 35.6622.1 43.3621.6 25.1618.4
d 31.1620.3 40.4623.2
Transplantation, n (%) 7 (9%) 7 (16%) 0 (0%)
a 5 (13%) 2 (5%)
Mean 6 SD [25., 50. und 75. percentile in case of non-normal distribution] or number (%).
ap,0.05;
bp,0.01;
cp,0.005;
dp,0.001 – comparison between survivors and non-survivors as well as between patients with and without cardiovascular disease events.
*Coronary artery disease events: myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass.
**Cardiovascular disease events: myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, angiographically-proven coronary
stenosis $50%, ischemic or hemorrhagic cerebral infarction, transient ischemic attack, carotid stenosis and carotid endarterectomy.
***Peripheral arterial disease events: significant ultrasound- or angiographically-proven vascular stenosis, percutaneous transluminal angioplasty, peripheral
bypass, amputation.
{Follow-up time was calculated as the time from the start of dialysis until the patient died or the end of the observation period was reached.
doi:10.1371/journal.pone.0020093.t001
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baseline and at the early observation period, we stratified patients
according to their baseline HbA1c values with a threshold of 7.0%
(Table 2). The 15 patients who died during the follow-up period
and having HbA1c values below 7% at baseline died mainly due to
therapy withdrawal (33%) and heart failure (27%). Two patients
stopped treatment because of sepsis, one patient due to end-stage
cancer, one patient due to an ischemic stroke and one patient
suffered from dementia. Only minor changes in HbA1c values
were observed between the baseline levels and the next measured
HbA1c level in these patients. In contrast, patients who died and
had HbA1c levels equal or above 7.0% at baseline died mainly due
to sepsis (33%), myocardial infarction (22%) or sudden cardiac
death (22%) (Table 2).
We did not observe a strong linear association between HbA1c
values and parameters of malnutrition such as albumin (r=0.033,
p=0.14), phosphorus (r=0.04, p=0.025) or CRP (r=20.002,
p=0.40). However, when we considered the association of HbA1c
below 7% with these parameters, we observed that lower albumin
and phosphorus concentrations and higher CRP values were
associated with HbA1c values below 7% (Table 3).
Patients who experienced a cardiovascular disease event during
the observation period had significantly higher HbA1c and albu-
min values at the baseline investigation before dialysis treatment
was started. HbA1c measurements were even higher when all
measurements during the whole observation period were consid-
ered (mean [95% CI]): 7.67 [7.15; 8.18] vs. 7.07 [7.04; 7.12].
Cox regression analysis
To make use of all information available from the entire
observation period, we considered HbA1c values as well as other
laboratory measurements from the entire observation period in
time-dependent regression models. This has the advantage that the
association is not based on a single baseline measurement but on
the glycemic control over the entire time of observation. Models
were calculated unadjusted, age- and sex-adjusted and with an
extended adjustment for blood pressure, albumin, CRP, hemo-
globin and previous CVD events. We observed a significant
inverse association between time-dependent HbA1c measurements
and all-cause mortality: the mortality risk decreased with
increasing HbA1c values (HR=0.72 per 1% increase, p=0.024).
After adjustment for age and sex and additional adjustment the
association was slightly attenuated but still significant (HR=0.71
per 1% increase, p=0.044) (Table 4). A non-linear P-spline on the
fully adjusted model showed this significant relationship between
decreasing HbA1c values and increasing risk of all-cause mortality
(Figure 2). The linear and the non-linear component of the non-
linear P-spline (p=0.034 and p=0.001) were significant (Table 4),
which implies that there is an overall negative trend, but that a
simple linear model resulting in one HR would not be sufficient to
describe the relationship between HbA1c values and time to event.
Figure 2 showed a decreasing trend up to HbA1c values of ,7%,
which flattens afterwards. This deviation from linearity is depicted
by the test of the non-linear part.
Furthermore, a borderline significant association could be found
between HbA1c measurements and CVD events. In contrast to all-
cause mortality, the risk for CVD events increased with increasing
HbA1c values (HR=1.24 per 1% increase, p=0.048). The
association vanished after adjusting for age and sex as well as
additional parameters (Table 4). A non-linear P-spline on the fully
adjusted model showed a trend for higher HbA1c values towards
an increasing risk of CVD events, but neither the linear nor the
non-linear component of the P-spline were significant (Figure 2
and Table 4). There was no significant association between HbA1c
values and the combination of CVD and PAD events (Table 4).
Sensitivity analysis
We performed a sensitivity analysis with censoring at the time of
transplantation which did, however, not reveal any substantial
Figure 1. Distribution of all 880 measured HbA1c values during
follow-up stratified for survivors and non-survivors.
doi:10.1371/journal.pone.0020093.g001
Table 2. Causes of death stratified by HbA1c ,7% vs. $7% at
baseline.
HbA1c at baseline (n=33)
Causes of death HbA1c ,7% (n=15) HbA1c $7% (n=18)
Myocardial infarction 2 (13%) 4 (22%)
Heart failure 4 (27%) 1 (6%)
Sudden cardiac death 1 (7%) 4 (22%)
Stroke 0 (0%) 1 (6%)
Sepsis/infection 2 (13%) 6 (33%)
Therapy withdrawal 5 (33%) 1 (6%)
End stage cancer 1 (7%) 0 (0%)
Other/unknown 0 (0%) 1 (6%)
doi:10.1371/journal.pone.0020093.t002
Table 3. Results from a linear mixed effects model of HbA1c
,7% on parameters of malnutrition and inflammation.
Effect estimate b P-value
Association of HbA1c ,7% with
Albumin (g/dL) 20.068 ,0.001
C-reactive protein (mg/dL) 0.326 0.008
Phosphorus (mmol/L) 20.062 0.001
doi:10.1371/journal.pone.0020093.t003
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unadjusted HR for all-cause mortality was 0.74 per 1% increase
(p=0.035), after adjustment for age and sex 0.73 (p=0.027) and
the HR was still significant after full adjustment (HR=0.72 per
1% increase, p=0.044). The non-linear component of the non-
linear P-spline was significant (p=0.002), the linear component
was borderline significant (p=0.052). We calculated a model with
additionally adjusting for BMI at baseline, which did not reveal
any major changes in HRs compared to the original extended
model. Two further sensitivity analyses were calculated where the
extended model was additionally adjusted for current smoking and
phosphorus levels, respectively. No substantial differences in HRs
for HbA1c could be observed.
Discussion
The study at hand used a time-dependent Cox regression
analysis of a single-center inception cohort of dialysis patients with
DM initiating dialysis treatment followed for up to more than
seven years. It used all information of HbA1c levels available from
the entire observation period to model the association of HbA1c
levels and all-cause mortality as well as CVD events and the
combination of CVD and PAD events. We observed an increased
risk of mortality for lower HbA1c values, but no association was
found for higher HbA1c levels. Furthermore, the risk for CVD
events increased with higher HbA1c values, but lacking statistical
significance.
The ACCORD trial [4], a prospective interventional study in
10,251 patients with DM without renal failure, investigated
whether HbA1c of ,6%, to be attained by intensive glucose
control, reduces CVD events and mortality. Surprisingly, they
found an increase in all-cause mortality in the intensive therapy
group compared to the standard therapy group. However, the
reduction in the primary outcome of nonfatal myocardial
infarction, nonfatal stroke or death from cardiovascular cause
with intensive therapy was not significant. It is unclear whether
dialysis patients with DM benefit from strict glycemic control [2].
Observational studies reported conflicting results concerning
glycemic control and large clinical trials have not been performed
in this patient population [19]. All studies investigating the
association between HbA1c and different clinical outcomes in
dialysis patients with DM are listed in Table 5 (studies which
found an association) and Table 6 (studies which did not find an
association). These studies were heterogeneous in several ways.
Firstly, some of them investigated a linear association of HbA1c
values with outcomes assuming a linear ‘‘dosage’’ association
between diabetic control and outcomes [5,10,11]. Other studies
compared the risk for outcomes above and below a certain
threshold which was either the median or mean of the inves-
tigated patient population [5,6,8,12] or a group-wise comparison
of the subjects above a certain threshold (poor controlled pa-
tients) against a ‘‘well controlled’’ group [7,9,10,13–16,20]. These
thresholds varied widely and did sometimes neglect the main
group of averaged controlled patients. To avoid this linear
‘‘dosage’’ assumption we used in our analysis non-linear P-splines
which allow modeling of the association without a priori as-
sumptions of thresholds. Our results point out that especially the
low HbA1c values are associated with an increased risk for
mortality.
A second heterogeneity between and within the studies derives
from the fact that most studies used only one HbA1c value and
patients were from mixed cohorts with patients either already
under dialysis treatment for various times or at the start of dialysis
treatment. To avoid this heterogeneity, we followed a single center
cohort of incident dialysis patients from a described geographical
region with full-ascertainment of all patients starting dialysis
treatment. Furthermore, we did not only use a baseline HbA1c
value but all HbA1c values of the entire observation period which
resulted in 880 values in total or one value on average every 3.16
months in each patient. This dense network of measurements used
Table 4. The association of time-dependent HbA1c with all-cause mortality, CVD events and the combination of CVD and PAD
events using multiple Cox-proportional hazards models.
All-cause mortality CVD events** CVD and PAD events***
(n events=33) (n events=38) (n events=52)
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Linear effect modeling
Adjustment: None 0.72 (0.54, 0.96) 0.024 1.24 (1.00, 1.54) 0.048 1.13 (0.95, 1.34) 0.164
Age, sex 0.71 (0.53, 0.95) 0.020 1.14 (0.87, 1.50) 0.338 1.05 (0.85, 1.29) 0.664
Extended* 0.71 (0.51, 0.99) 0.044 1.09 (0.82, 1.46) 0.554 1.04 (0.84, 1.28) 0.735
Non-linear effect modeling using P-splines
Adjustment: None Linear part 0.70 (0.58, 0.85) ,0.001 1.20 (0.99, 1.46) 0.063 1.10 (0.93, 1.26) 0.280
Non-linear part 0.007 0.039 0.070
Age, sex Linear part 0.69 (0.56, 0.84) ,0.001 1.10 (0.87, 1.38) 0.420 1.01 (0.82, 1.21) 0.890
Non-linear part 0.008 0.074 0.094
Extended* Linear part 0.81 (0.66, 0.98) 0.034 1.05 (0.83, 1.33) 0.680 1.01 (0.82, 1.20) 0.900
Non-linear part 0.001 0.110 0.170
For each model, estimated HRs are shown for the linear component of the non-linear P-spline as well as HRs for HbA1c measurements per 1% increase.
*Adjusted for age, sex, time-dependent systolic blood pressure, diastolic blood pressure, albumin, CRP, hemoglobin and previous CVD **.
**Cardiovascular disease events: myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, angiographically-proven coronary
stenosis $50%, ischemic or hemorrhagic cerebral infarction, transient ischemic attack, carotid stenosis and carotid endarterectomy.
***Cardiovascular and peripheral arterial disease events: CVD events or significant ultrasound- or angiographically-proven vascular stenosis, percutaneous
transluminal angioplasty, peripheral bypass, amputation.
doi:10.1371/journal.pone.0020093.t004
Association of HbA1c with Mortality and CVD Events
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20093in a time-dependent Cox regression modeling has the major
advantage that not a single measurement is the basis of the anal-
ysis but a complete coverage of the glycemic control during the
observation period. In our case this was even extended by not only
considering the HbA1c values but also each single measured value
of blood pressure, albumin, CRP and hemoglobin during the
entire observation period as well as the occurrence of a CVD event
before dialysis treatment was initiated.
There are only two other studies which applied time-dependent
modeling of HbA1c values in patients with DM. A study of almost
24,000 US hemodialysis patients with DM done by Kalantar-
Zadeh et al. [16] followed HbA1c values for 3 years and averaged
all measures for each patient during any given calendar quarter.
HbA1c values were divided into categories reaching from ,5% to
$10%, and 1% increments in between. They observed lower
unadjusted mortality to be associated with poor glycemic control,
however, after adjustment for potential confounders the direction
of the association changed and higher HbA1c levels were now
incrementally associated with higher death risks. They also stated
that one-third of all prevalent diabetic hemodialysis patients in
the US have HbA1c values within the normal range comparable
to the general population. Previous hyperglycemia that caused
their micro- or macrovascular disease appeared to be ‘‘burnt-out’’
by complex pathophysiologic mechanisms [16]. Shurraw et al.
[13] investigated the association of HbA1c and all-cause mortality
in a retrospective cohort of 448 hemodialysis patients with DM.
They did not find any association between HbA1c levels and
mortality.
Only one interventional study in dialysis patients with DM by
McMurray et al. [21] revealed that intensive diabetes education
and care management leading to improvements in patient out-
comes, glycemic control and a better quality of life. Nonetheless,
after a 12-month period no statistically significant difference in
survival benefit between the intensive intervention group and
control group could be observed. In a prospective interventional
study in patients with DM but without renal failure [4] an
increased risk of mortality for low HbA1c values could be found,
however, up to now there was no study in dialysis patients with
DM supporting this finding. Our patients were under long-term
observation up to seven years and we might speculate that
intensive diabetic control increases the risk for hypoglycemic
episodes which with increasing frequency increases the risk to die
in the long-run. On the other hand it is interesting that non-
survivors who had HbA1c levels below 7% at baseline and during
the first 3 months of follow-up died mostly from chronic heart
failure and therapy withdrawal. This favors the idea that those
non-survivors with low HbA1c died mainly due to a bad general
health condition than due to an intensive diabetes control. As an
example, weight loss due to an intercurrent illness or malnutrition
may by itself lead to lower HbA1c levels. This is in line with our
observation that HbA1c below 7% was associated with signifi-
cantly lower albumin and phosphorus concentrations and higher
CRP levels (Table 3). In addition, it is well known that low HbA1c
levels in dialysis patients may not be caused by better glycemic
control, but a shortened life span of erythrocytes [22,23]. In both
studies, HbA1c correlated positively with hemoglobin levels and
negatively with the administered erythropoietin dose. Thus, low
HbA1c may also be a consequence of erythropoietin resistance,
which in many instances is caused by some intercurrent illness
and inflammation.
Strength and limitations of the study
The prospective recruitment of all patients starting dialysis
treatment over a period of six years in a clearly described geo-
graphic area allowed a complete ascertainment of incident dialysis
patients over a defined period of time with almost no loss to follow-
up during a long observation period. Therefore the most
important bias of cross-sectional studies with a mix of prevalent
and incident cases and the resulting survival bias can be excluded
when it comes to survival bias after start of renal replacement
therapy. On the other hand it might lack generalizability to other
ethnic populations as well as other recruitment procedures. A
Figure 2. Cox regression results: P-splines to explore the
functional form of the effect of HbA1c values on the log hazard
ratio for the risk of a) all-cause mortality and of b) cardiovas-
cular disease events, adjusted for age, sex, time-dependent
systolic blood pressure, diastolic blood pressure, albumin,
CRP, hemoglobin and previous CVD. Dashed lines are the
pointwise 95% CI. The rugplot at the bottom of the figures displays
the number of measurements.
doi:10.1371/journal.pone.0020093.g002
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20093Table 5. Studies in dialysis patients with diabetes mellitus which found an association between HbA1c and different clinical
outcomes.
Study Design Follow-up Endpoint (number of patients with endpoint): HR (95% CI)
Drechsler et al. Observational cohort study: 4 yrs. a) HbA1c .8% vs. HbA1c #6%; b) per 1% HbA1c increase; multivariable
adjustment.
2010 [10] 1255 German HD patients CVD (n=469): a) HR=1.37 (1.00–1.87); b) HR=1.09 (1.01–1.18)
All-cause mortality (n=617): a) HR=1.34 (1.02–1.76); b) HR=1.09 (1.02–1.17)
Sudden death (n=160): a) HR=2.26 (1.33–3.85); b) HR=1.21 (1.06–1.38)
MI (n=200): a) HR=0.77 (0.47–1.26)
Stroke (n=103): a) HR=1.67 (0.84–3.30)
Heart failure death (n=41): a) HR=2.12 (0.75–5.98)
Ishimura et al. 2009 [5] Observational cohort study: 55.5 mos. a) HbA1c $6.3% vs. HbA1c ,6.3%; b) per 1% increase; adjusted for age, sex,
duration of HD.
122 Japanese HD patients All-cause mortality (n=37): a) HR=2.879 (1.439–5.759)
CV mortality n=19): a) HR=2.749 (1.064–7.089)
Non-CV mortality (n=18): a) HR=3.196 (1.171–8.724); b) HR=1.418 (1.063–1.892)
Kalantar-Zadeh et al. Prospective cohort study: 3 yrs. All-cause mortality*, unadjusted: HR=0.87 (0.82–0.89) for HbA1c .6% vs.#6%
2007 [16] 23,618 US HD patients All-cause mortality*, multivariate adjustment: HR=1.05 (1.01–1.10) for HbA1c .6% vs. #6%
CV mortality*, multivariate adjustment: HR=1.73 (1.44–2.08) for HbA1c $10% vs. 5.0–5.9%)
Morioka et al. 2001 [6] Prospective cohort study: 150
Japanese incident HD patients
2.7 yrs. All-cause mortality (n=72): HR=1.13 (1.028–1.249) for HbA1c $7.5% vs.HbA1c ,7.5%;
adjusted for age and sex.
Oomichi et al. 2006 [7] Observational cohort study:
114 Japanese HD patients
45.5 mos. All-cause mortality (n=72): HR=2.89 (1.538–5.429) for HbA1c $8% vs. HbA1c ,6.5%;
adjusted for age, sex, duration of HD, CVD.
Tsujimoto et al. 2009 [8] Prospective cohort study: 134
Japanese HD patients
5 yrs. CVD (n=50): HR=1.828 (1.008–3.314) for HbA1c $7% compared with HbA1c ,7%;
adjusted for age, sex, duration of HD, CVD.
Williams et al. 2009 [20] Retrospective cohort study:
23,829 US HD patients
1 yr. Hospitalization risk (71.2%): Association only with extremes of HbA1c (,5 and .11%);
multivariable adjustment.
>Wu et al. 1997 [9] Retrospective cohort study: 137
Taiwanese HD patients
1–5 yrs. All-cause mortality (n=48): HR=0.37 (0.175–0.795) for HbA1c ,10% compared with
HbA1c $10%; adjusted for age, albumin and cholesterol.
CV, cardiovascular; CVD cardiovascular disease; MI myocardial infarction; HD hemodialysis.
*exact numbers of events are not available.
doi:10.1371/journal.pone.0020093.t005
Table 6. Studies in dialysis patients with diabetes mellitus which did not find an association between HbA1c and different clinical
outcomes.
Study Design Follow-up Endpoint (number of patients with endpoint): HR (95% CI)
Fukuoka et al. 2008 [11] Prospective cohort study: 47.7 mos. per 1% HbA1c increase; adjusted for age, sex, total cholesterol, CRP and albumin.
98 Japanese HD patients All-cause mortality (n=51): HR=0.929 (0.734–1.175)
CV mortality (n=22): HR=1.345 (0.867–2.086)
Infectious death (n=16): HR=1.078 (0.696–1.689)
McMurray et al.
2002 [21]
Non-randomized trial: 83
US HD patients
1 yr. Quality of life: no survival benefit; HbA1c levels significantly decreased and quality of life
was significantly improved in the study group;
Okada et al. 2007 [12] Prospective cohort study: 3 yrs. a) per 1% HbA1c increase; b) HbA1c $6.43% vs. ,6.43%; multivariate adjustment.
78 Japanese HD patients All-cause mortality (n=27): a) HR=1.11 (0.71–1.74); b) HR=0.93 (0.34–2.58)
CV mortality (n=15): a) HR=1.04 (0.48–2.28); b) HR=1.06 (0.16–7.12)
CVD (n=23): CVD: a) HR=1.34 (0.78–2.29); b) HR=0.81 (0.27–2.46)
Shima et al. 2010 [15] Observational cohort study:
245 Japanese HD patients
43.2 mos. All-cause mortality (n=68): HR=0.712 (0.315–1.609) for HbA1c $7% vs. ,6.0%;
multivariate adjustment.
Shurraw et al. 2010 [13] Retrospective cohort study: 540
Canadian incident HD patients (448
of them with diabetes mellitus)
1.5 yrs. All-cause mortality (n=236): a) per 1% HbA1c increase, unadjusted: HR=1.01 (0.92–1.11);
b) HbA1c $9% vs. ,7%, multivariate adjustment: HR=1.06 (0.55–2.07).
Williams et al. 2006 [14] Observational cohort study:
24,875 US HD patients
1 yr. All-cause mortality (15–20%): no clear patterns between HbA1c and death risk;
multivariable adjustment.
CV, cardiovascular; CVD cardiovascular disease; HD hemodialysis.
doi:10.1371/journal.pone.0020093.t006
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the number of variables for which the analysis can be adjusted.
However, there were no differences for the age- and sex-adjusted
models and the models with extended adjustment. Even if the
sample size might have limited the generalizability of our findings,
our study might be a stimulus for other studies which have the data
with this depth (duration of observation and granularity of data
points) available for analysis.
Despite these limitations our study has notable strengths. It is a
single center study with uniform laboratory measurements of high
frequency and continuity collected over a period of up to seven
years. By analyzing HbA1c on risk of mortality, CVD events and
the combination of CVD and PAD events in a time-dependent
modeling framework, we were able to include all measurements
over the whole observation period. Our study is up to now the only
inception cohort study with time-dependent measurements over a
long observation period.
Conclusions
Our prospective observational cohort study of patients with DM
initiating dialysis treatment considered the entire information
collected on HbA1c over a period of more than seven years and
observed a significant association between low HbA1c levels and
all-cause mortality. Based on the causes of death we suspect that
the low HbA1c levels associated with increased mortality were not
a consequence of intensive glucose-lowering therapy, but rather
caused by poor general health condition. For CVD events and the
combination of CVD and PAD events no significant association
with HbA1c levels could be observed.
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